HCPCS J0217 is officially defined as "Injection, velmanase alfa-tycv, 1 mg." HCPCS J0217 is referenced in 3 tracked payer policy changes from UnitedHealthcare, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J0217 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
UnitedHealthcare Community Plan of Arizona is denying payment for two specialty drugs (Lamzede [J0217] and Zevaskyn [J3389]) when billed on medical professional or outpatient facility claims. These injectable medications must now be reimbursed exclusively through the outpatient pharmacy benefit to comply with Arizona's Catastrophic Reinsurance Program requirements.
Aetna's commercial policy for lysosomal storage disorder treatments covers each enzyme replacement drug for the diagnoses and criteria listed, including Fabry disease, Pompe disease, Gaucher disease, MPS I, II, IVA, VI and VII, CLN2, acid sphingomyelinase deficiency, lysosomal acid lipase deficiency and alpha-mannosidosis. Lumizyme and Pombiliti are medically necessary only for members who have a contraindication, intolerance or ineffective response to Nexviazyme, and VPRIV is medically necessary only for members who have a contraindication, intolerance or ineffective response to both Cerezyme and Elelyso. Continuation of therapy is covered only for members who are responding to therapy.
Independence Blue Cross reissued MA08.147 on 05/28/2025 with no substantive changes to communicate the company's continuing coverage position for velmanase alfa-tycv (Lamzede) for non-CNS manifestations of alpha-mannosidosis in pediatric and adult patients age 3+. The policy remains unchanged from its original 03/11/2024 effective date, including all coverage criteria, continuation requirements, and dosing specifications.
Watch J0217
Get one email when a payer policy names J0217, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J0217
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J0217 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.